Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models
MetadataShow full item record
Background: The natural polyphenol myricetin induces cell cycle arrest and apoptosis in preclinical cancer models. We hypothesised that myricetin-derived flavonoids with enhanced redox properties, improved cell uptake and mitochondrial targeting might have increased potential as antitumour agents. Methods: We studied the effect of a second-generation flavonoid analogue, Oncamex, in a panel of 7 breast cancer cell lines, applying western blotting, gene expression analysis, fluorescence microscopy, and immunohistochemistry to xenograft tissue to investigate its mechanism of action. Results: Proliferation assays showed that Oncamex: treatment for 8 h reduced cell viability and induced cytotoxicity and apoptosis, concomitant with increased caspase activation. Microarray analysis showed that Oncamex was associated with changes in expression of genes controlling cell cycle and apoptosis . Fluorescence microscopy showed the compound’s mitochondrial targeting and ROS-modulating properties, inducing superoxide production at concentrations associated with anti-proliferative effects. A preliminary in vivo study in mice implanted with the MDA-MB-231 breast cancer xenograft showed that Oncamex inhibited tumour growth, reduced tissue viability and Ki-67 proliferation, with no overall systemic toxicity. Conclusion: Oncamex is a novel flavonoid capable of specific mitochondrial delivery and redox modulation. It has shown antitumour activity in preclinical models of breast cancer, supporting the potential of this prototypic candidate for its continued development as an anticancer agent.
Martínez-Pérez , C , Ward , C , Turnbull , A K , Mullen , P , Cook , G , Meehan , J , Jarman , E J , Thomson , P I T , Campbell , C J , McPhail , D , Harrison , D J & Langdon , S P 2016 , ' Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models ' , British Journal of Cancer , vol. 114 , no. 8 , pp. 905-916 . https://doi.org/10.1038/bjc.2016.6
British Journal of Cancer
This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
DescriptionWe thank SULSA (Scottish Universities Life Science Alliance) for supporting this project through a SULSA BioSkape Industry PhD Studentship and Antoxis Limited for providing additional funding. We also thank the 7th Framework Programme of the European Union (METOXIA project; HEALTH-F2-2009-222741) for support.
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Showing items related by title, author, creator and subject.
"Will it affect our chances of having children?" and feeling "like a ticking bomb" —the fertility concerns and fears of cancer progression and recurrence in cancer treatment decision-making among young women diagnosed with gynaecological or breast cancer Sobota, Aleksandra; Ozakinci, Gozde (2021-06-02) - Journal articleObjective Cancer treatment decision making process is particularly fraught with challenges for young women because the treatment can affect their reproductive potential. Among many factors affecting the process, fears of ...
Determinants of fertility issues experienced by young women diagnosed with breast or gynaecological cancer - a quantitative, cross-cultural study Sobota, Aleksandra; Ozakinci, Gozde (2018-09-06) - Journal articleBackground. Although there is a recognition of the importance of fertility to young women with cancer, we do not know who is at risk of distress related to fertility issues following diagnosis. We investigated the determinants ...
Does cancer type influence the impact of recurrence? : a review of the experience of patients with breast or prostate cancer recurrence Stewart, Ross James; Humphris, Gerald Michael; Donaldson, Jayne; Cruickshank, Susanne (2021-06-29) - Journal articleObjective Patients will experience a plethora of issues when faced with a recurrence of their cancer. It is unclear if cancer type is a significant factor in how recurrence is experienced by an individual. The aim of the ...